JETEMA Past Earnings Performance
Past criteria checks 2/6
JETEMA has been growing earnings at an average annual rate of 859.9%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 27.7% per year. JETEMA's return on equity is 18.3%, and it has net margins of 23.8%.
Key information
859.9%
Earnings growth rate
857.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 27.7% |
| Return on equity | 18.3% |
| Net Margin | 23.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News
Mar 23
Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?
Feb 25JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt
Jan 21The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?
Dec 17
Revenue & Expenses BreakdownBeta
How JETEMA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 58,716 | 13,966 | 13,249 | 10,223 |
| 30 Sep 23 | 57,603 | -21,990 | 13,922 | 8,782 |
| 30 Jun 23 | 55,439 | -18,144 | 13,707 | 7,449 |
| 31 Dec 22 | 45,994 | 1,455 | 11,955 | 6,263 |
Quality Earnings: A216080 has a large one-off gain of ₩651.2M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A216080's current net profit margins (23.8%) are higher than last year (3.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A216080's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A216080's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: A216080 earnings growth over the past year (859.9%) exceeded the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: A216080's Return on Equity (18.3%) is considered low.